Literature DB >> 23417321

Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma.

Shi-Yong Wang1, Yi-Quan Ke, Guo-Hui Lu, Zhen-Hua Song, Li Yu, Sha Xiao, Xin-Lin Sun, Xiao-Dan Jiang, Zhi-Lin Yang, Chang-Chen Hu.   

Abstract

A previous report has confirmed the existence and clinical significance of vasculogenic mimicry (VM) in glioma. However, its conclusions about the negative clinical significance of VM in glioblastoma are based on a small group of patients and, thus, might be unconvincing. The aim of the present study was to reevaluate the clinical significance of VM in glioblastoma. Patients were classified as VM-positive or VM-negative according to CD34 and periodic acid-Schiff staining. The association between VM and the clinical characteristics of the patients was analyzed. Univariate and multivariate analyses were carried out to identify the independent prognostic factors for overall survival using the Cox regression hazard model. Survival times were estimated using the Kaplan-Meier method and compared using the log-rank test. Of all 86 glioblastomas, 23 were found to have VM. The presence of VM in glioblastoma was not associated with gender, age, Karnofsky performance status, hydrocephalus, tumor burden, microvessel density, tumor relapse, or the extent of tumor resection. The univariate and multivariate analyses revealed that VM is an independent prognostic factor for overall survival. The median survival time for patients with VM was 11.17 months compared with 16.10 months for those without VM (P = 0.017). In addition to VM, an age of 65 years or older, a KPS of 60 or less, a large tumor burden are significant prognostic factors for patient survival. Our data suggest that VM might be an independent adverse prognostic factor in newly diagnosed GBM, further prospective studies are needed to answer this question.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417321     DOI: 10.1007/s11060-013-1077-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia.

Authors:  Daisy W J van der Schaft; Femke Hillen; Patrick Pauwels; Dawn A Kirschmann; Karolien Castermans; Mirjam G A Oude Egbrink; Maxine G B Tran; Rafael Sciot; Esther Hauben; Pancras C W Hogendoorn; Olivier Delattre; Patrick H Maxwell; Mary J C Hendrix; Arjan W Griffioen
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

2.  Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications.

Authors:  Dawn A Kirschmann; Elisabeth A Seftor; Katharine M Hardy; Richard E B Seftor; Mary J C Hendrix
Journal:  Clin Cancer Res       Date:  2012-04-02       Impact factor: 12.531

3.  Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells.

Authors:  Xin-Lin Sun; Zhi-Min Xu; Yi-Quan Ke; Chang-Chen Hu; Shi-Yong Wang; Geng-Qiang Ling; Zhong-Jie Yan; Yi-Jing Liu; Zhen-Hua Song; Xiao-Dan Jiang; Ru-Xiang Xu
Journal:  Cancer Lett       Date:  2011-08-17       Impact factor: 8.679

4.  Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation.

Authors:  Jun Dong; Yaodong Zhao; Qiang Huang; Xifeng Fei; Yi Diao; Yuntian Shen; Hong Xiao; Tianyi Zhang; Qing Lan; Xiaosong Gu
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

5.  Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors.

Authors:  Baocun Sun; Shuo Qie; Shiwu Zhang; Tao Sun; Xiulan Zhao; Songyuan Gao; Chunsheng Ni; Xinghui Wang; Yanxue Liu; Lihua Zhang
Journal:  Hum Pathol       Date:  2008-03       Impact factor: 3.466

6.  Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas.

Authors:  Baocun Sun; Shiwu Zhang; Xiulan Zhao; Wei Zhang; Xishan Hao
Journal:  Int J Oncol       Date:  2004-12       Impact factor: 5.650

7.  Survival prognostic factors in patients with glioblastoma: our experience.

Authors:  S Raysi Dehcordi; D De Paulis; S Marzi; A Ricci; A Cimini; M G Cifone; R J Galzio
Journal:  J Neurosurg Sci       Date:  2012-09       Impact factor: 2.279

8.  Clinical significance of vasculogenic mimicry in human gliomas.

Authors:  Xiao-mei Liu; Qing-ping Zhang; Yong-gao Mu; Xiang-hen Zhang; Ke Sai; Jesse Chung-Sean Pang; Ho-Keung Ng; Zhong-ping Chen
Journal:  J Neurooncol       Date:  2011-04-30       Impact factor: 4.130

9.  The value of glioma extent of resection in the modern neurosurgical era.

Authors:  Douglas A Hardesty; Nader Sanai
Journal:  Front Neurol       Date:  2012-10-18       Impact factor: 4.003

10.  Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas.

Authors:  Hiromi Kanno; Hiroshi Nishihara; Takuhito Narita; Shigeru Yamaguchi; Hiroyuki Kobayashi; Mishie Tanino; Taichi Kimura; Shunsuke Terasaka; Shinya Tanaka
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more
  27 in total

1.  Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.

Authors:  Signe Regner Michaelsen; Thomas Urup; Lars Rønn Olsen; Helle Broholm; Ulrik Lassen; Hans Skovgaard Poulsen
Journal:  J Neurooncol       Date:  2018-01-05       Impact factor: 4.130

2.  LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.

Authors:  Xi Zhang; Qian Song; Chunyan Wei; Jianqiang Qu
Journal:  Cell Stress Chaperones       Date:  2015-04-10       Impact factor: 3.667

Review 3.  Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry.

Authors:  Elena Andreucci; Silvia Peppicelli; Jessica Ruzzolini; Francesca Bianchini; Lido Calorini
Journal:  Cancer Metastasis Rev       Date:  2022-10-13       Impact factor: 9.237

4.  MEK/ERK pathway is positively involved in hypoxia-induced vasculogenic mimicry formation in hepatocellular carcinoma which is regulated negatively by protein kinase A.

Authors:  Bin Huang; Enhua Xiao; Manping Huang
Journal:  Med Oncol       Date:  2014-12-09       Impact factor: 3.064

5.  Caveolin-1 promotes tumor cell proliferation and vasculogenic mimicry formation in human glioma.

Authors:  Wenli Chen; Xing Cheng; Xiaobo Wang; Wenjie Hu; Jinshan Wang; Chuangxin Liao
Journal:  Braz J Med Biol Res       Date:  2021-07-16       Impact factor: 2.590

6.  Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets.

Authors:  Jin-Ming Mao; Jing Liu; Geng Guo; Xing-Gang Mao; Chang-Xin Li
Journal:  Biomark Res       Date:  2015-04-18

Review 7.  Advanced research on vasculogenic mimicry in cancer.

Authors:  Lili Qiao; Ning Liang; Jiandong Zhang; Jian Xie; Fengjun Liu; Deguo Xu; Xinshuang Yu; Yuan Tian
Journal:  J Cell Mol Med       Date:  2015-01-19       Impact factor: 5.310

8.  Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway.

Authors:  Xiao Liu; Ji-Hui Wang; Shun Li; Lin-Lin Li; Min Huang; Yong-Hong Zhang; Yang Liu; Yuan-Tao Yang; Rui Ding; Yi-Quan Ke
Journal:  Cancer Sci       Date:  2015-06-18       Impact factor: 6.716

9.  CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.

Authors:  Carmela Martini; Mark DeNichilo; Danielle P King; Michaelia P Cockshell; Brenton Ebert; Brian Dale; Lisa M Ebert; Anthony Woods; Claudine S Bonder
Journal:  BMC Cancer       Date:  2021-07-02       Impact factor: 4.430

10.  All-trans retinoic acid impairs the vasculogenic mimicry formation ability of U87 stem-like cells through promoting differentiation.

Authors:  Geng-Qiang Ling; Yi-Jing Liu; Yi-Quan Ke; Lei Chen; Xiao-Dan Jiang; Chuan-Lu Jiang; Wei Ye
Journal:  Mol Med Rep       Date:  2015-03-06       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.